<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423447</url>
  </required_header>
  <id_info>
    <org_study_id>27689</org_study_id>
    <nct_id>NCT02423447</nct_id>
  </id_info>
  <brief_title>Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With CF</brief_title>
  <official_title>Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With Cystic Fibrosis (CF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the goal of the proposed study to compare the efficacy, as assessed primarily by sputum
      weight, of these two different devices (the Electroflo 500 and the G5 Flimm-Fighter) for
      airway clearance (AC) in CF patients with mild to moderate lung disease, who have stable lung
      health and perform AC at home as part of their routine therapeutic regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hope to enroll 25 patients with cystic fibrosis (with daily sputum
      production) in this study. It is the goal of the proposed study to compare the efficacy, as
      assessed primarily by sputum weight, of these two different devices (the Electroflo 500 and
      the G5 Flimm-Fighter) for airway clearance (AC) in CF patients with mild to moderate lung
      disease, who have stable lung health and perform AC at home as part of their routine
      therapeutic regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wet Sputum Weight</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>To compare the wet to dry weight of study patients' sputum collected during their Day 1 &amp; Day 2 therapy sessions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dry Sputum Weight</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>To compare the wet to dry weight of study patients' sputum collected during their Day 1 &amp; Day 2 therapy sessions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary Function Measured as a Percent Predicted AFTER Therapy With Either ElectroFlo 5000 / G5.</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Measured as a Percent Predicted BEFORE Therapy With Either ElectroFlo 5000 / G5.</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRO (Patient-reported Outcome)</measure>
    <time_frame>End of study visit per intervention</time_frame>
    <description>Investigators will question the study patients re: their tolerability and comfort after the intervention on Day 1 &amp; Day 2 visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Electro-Flo Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G5 Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electro-Flo Intervention</intervention_name>
    <description>An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines</description>
    <arm_group_label>Electro-Flo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G5 Intervention</intervention_name>
    <description>An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines</description>
    <arm_group_label>G5 Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of CF established by standard criteria (sweat chloride &gt; 60 mmol/L and/or
             two alleles affected by gene mutations know to be associated with CF).

          2. Age older than 8 years.

          3. Known to consistently produce sputum.

          4. Currently on a home therapeutic regimen that includes some form of AC performed at
             least 1 time daily.

          5. FEV1 &gt; 30%-predicted, and with stable lung function

        Exclusion Criteria:

          1. Hospitalization for CF pulmonary complications in the 1 months preceding enrollment.

          2. Hemoptysis &gt; 60 cc in a single episode in the 4 weeks preceding enrollment.

          3. Chronic chest pain.

          4. Participation in another interventional clinical trial in the previous 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Milla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <results_first_submitted>August 13, 2015</results_first_submitted>
  <results_first_submitted_qc>December 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2016</results_first_posted>
  <last_update_submitted>December 7, 2015</last_update_submitted>
  <last_update_submitted_qc>December 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Carlos Milla</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Electro-Flo, Then G5</title>
          <description>The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
Electro-Flo Intervention: An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines</description>
        </group>
        <group group_id="P2">
          <title>G5, Then Electro-Flo</title>
          <description>The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
G5 Intervention: An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants had the diagnosis of cystic fibrosis. All enrolled had baseline sputum production and were deemed at their baseline health status.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Electro-Flo Intervention: An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines.
G5 Intervention: An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Basline Pulmonary Function (FEV1)</title>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.42" spread="20.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wet Sputum Weight</title>
        <description>To compare the wet to dry weight of study patients' sputum collected during their Day 1 &amp; Day 2 therapy sessions.</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ElectroFlo Arm</title>
            <description>ElectroFlo Arm</description>
          </group>
          <group group_id="O2">
            <title>G5 Flimm Fighter Arm</title>
            <description>G5 Flimm Fighter arm</description>
          </group>
        </group_list>
        <measure>
          <title>Wet Sputum Weight</title>
          <description>To compare the wet to dry weight of study patients' sputum collected during their Day 1 &amp; Day 2 therapy sessions.</description>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" lower_limit="0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="4.19" lower_limit="0" upper_limit="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function Measured as a Percent Predicted BEFORE Therapy With Either ElectroFlo 5000 / G5.</title>
        <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Electro-Flo Arm</title>
            <description>Electro-Flo arm
Electro-Flo Intervention: An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines</description>
          </group>
          <group group_id="O2">
            <title>G5 Arm</title>
            <description>G5 arm
G5 Intervention: An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Measured as a Percent Predicted BEFORE Therapy With Either ElectroFlo 5000 / G5.</title>
          <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
          <units>percentage of predicted value</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.16" lower_limit="49.25" upper_limit="89.07"/>
                    <measurement group_id="O2" value="69.84" lower_limit="49.61" upper_limit="90.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRO (Patient-reported Outcome)</title>
        <description>Investigators will question the study patients re: their tolerability and comfort after the intervention on Day 1 &amp; Day 2 visits.</description>
        <time_frame>End of study visit per intervention</time_frame>
        <population>Patients rated comfort on a scale of 1 (most comfortable) to 10 (most un-comfortable)</population>
        <group_list>
          <group group_id="O1">
            <title>Electro-Flo Arm</title>
            <description>Electro-Flo arm
Electro-Flo Intervention: An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines</description>
          </group>
          <group group_id="O2">
            <title>G5 Arm</title>
            <description>G5 arm
G5 Intervention: An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>PRO (Patient-reported Outcome)</title>
          <description>Investigators will question the study patients re: their tolerability and comfort after the intervention on Day 1 &amp; Day 2 visits.</description>
          <population>Patients rated comfort on a scale of 1 (most comfortable) to 10 (most un-comfortable)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" lower_limit="1.03" upper_limit="5.45"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.58" upper_limit="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dry Sputum Weight</title>
        <description>To compare the wet to dry weight of study patients' sputum collected during their Day 1 &amp; Day 2 therapy sessions.</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Electro-Flo Arm</title>
            <description>Electro-Flo arm Electro-Flo device following the 2012 CFF therapy guidelines</description>
          </group>
          <group group_id="O2">
            <title>G5 Arm</title>
            <description>G5 arm
G5 Intervention: An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Dry Sputum Weight</title>
          <description>To compare the wet to dry weight of study patients' sputum collected during their Day 1 &amp; Day 2 therapy sessions.</description>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Function Measured as a Percent Predicted AFTER Therapy With Either ElectroFlo 5000 / G5.</title>
        <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
        <time_frame>End of study visit per intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Electro-Flo Arm</title>
            <description>Electro-Flo arm
Electro-Flo Intervention: An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines</description>
          </group>
          <group group_id="O2">
            <title>G5 Arm</title>
            <description>G5 arm
G5 Intervention: An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function Measured as a Percent Predicted AFTER Therapy With Either ElectroFlo 5000 / G5.</title>
          <description>Comparison of pulmonary function by doing spirometry testing on study patients during their Day 1 &amp; Day 2 therapy sessions. Will also compare the results based on the therapies they receive.</description>
          <units>percentage of predicted value</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.36" lower_limit="51.08" upper_limit="91.64"/>
                    <measurement group_id="O2" value="71.52" lower_limit="51.45" upper_limit="91.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Electro Flo</title>
          <description>Electro flo</description>
        </group>
        <group group_id="E2">
          <title>G5 Flimm Fighter</title>
          <description>G5 Flimm Fighter</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carlos Milla, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-5193</phone>
      <email>cmilla@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

